Antithrombin therapy, antiplatelet therapy and percutaneous coronary intervention: rationale and design of the SYNERGY trial

Although low-molecular-weight (LMWHs) have been shown to be equivalent or superior to unfractionated heparin for the management of patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), a number of clinical issues remain. Among them are the safety of bringing patients to the catheterization laboratory and the use of glycoprotein (GP)IIb IIIa antagonists. The superior Yield of the New strategy of Enoxaparin. Revascularization and GlYcoprotein IIb IIIa inhibitors (SYNERGY) trial is a randomized study comparing the safety and efficacy of unfractionated heparin and the LMWH enoxaparin in high-risk, invasively managed UA NSTEMI patients who are likely to receive GPIIb IIIa antagonists. (C) 2002 The European Society of Cardiology.